# RETRACTION: Evaluation of Bevacizumab Biosimilar on Wound Healing Complications in Patients with Colorectal Cancer Undergoing Endoscopic Mucosal Resection: A Systematic Review and Meta‐Analysis in Anorectal Medicine

## TL;DR

This retracted study claimed to evaluate a biosimilar drug's effect on wound healing in colorectal cancer patients but was found to have used a compromised peer review process.

## Contribution

The paper's findings and conclusions are invalid due to a flawed peer review process.

## Key findings

- The article was retracted due to a compromised peer review process.
- The authors did not respond to the retraction notice.
- The study's results cannot be trusted or relied upon.

## Abstract

RETRACTION:

LiY.
,
MeiZ.
,
ShiL.
,
WanY.
,
ZhouX.
,
ZengT.
,
LiuY.
,
YangJ. Y.
, and
ShiZ.
, “Evaluation of Bevacizumab Biosimilar on Wound Healing Complications in Patients with Colorectal Cancer Undergoing Endoscopic Mucosal Resection: A Systematic Review and Meta‐Analysis in Anorectal Medicine,” International Wound Journal
21, no. 1 (2024): e14638, 10.1111/iwj.14638.38272807
PMC10805537

The above article, published online on 23 January 2024, in Wiley Online Library (http://onlinelibrary.wiley.com/), has been retracted by agreement between the journal Editor in Chief, Professor Keith Harding; and John Wiley & Sons Ltd. Following an investigation by the publisher, all parties have concluded that this article was accepted solely on the basis of a compromised peer review process. The editors have therefore decided to retract the article. The authors did not respond to our notice regarding the retraction.